<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01465841</url>
  </required_header>
  <id_info>
    <org_study_id>CLP 4492</org_study_id>
    <secondary_id>CLP 4492</secondary_id>
    <nct_id>NCT01465841</nct_id>
  </id_info>
  <brief_title>Study of the Penumbra Coil 400 System to Treat Aneurysm</brief_title>
  <acronym>ACE</acronym>
  <official_title>ACE: An Aneurysm Coiling Efficiency Study of the Penumbra Coil 400 System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penumbra Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Penumbra Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center study of patients with intracranial or peripheral
      aneurysms who are treated by the PC 400 System. The primary objective is to gather post
      market data on the Penumbra Coil 400 (PC 400) System in the acute treatment of intracranial
      and peripheral aneurysms. Approximately 2,000 patients with intracranial or peripheral
      aneurysms treated by the PC 400 System at up to 100 centers will be enrolled. Data for each
      patient are collected up to discharge or 3 days post-procedure, whichever occurs sooner. Long
      term follow-up to one year will be conducted in accordance to the standard of care at each
      participating hospital.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Packing Density With the Number of Coils Implanted</measure>
    <time_frame>At immediate post-procedure</time_frame>
    <description>The data will be captured at the end of the coiling procedure which is standard for aneurysm studies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Fluoroscopic Exposure</measure>
    <time_frame>At immediate post-procedure</time_frame>
    <description>The total time of fluoroscopic exposure will be captured from the initial recording of the road map to the final angiogram after completion of the coiling procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural Device-related Serious Adverse Events</measure>
    <time_frame>At immediate post-procedure</time_frame>
    <description>Procedural on-the-table serious adverse events will be captured and recorded at the end of the procedure. The duration of the procedure can be variable, depending on the time to access the target lesion and the time to complete the coiling procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Occlusion of the Aneurysm Sac</measure>
    <time_frame>At immediate post-procedure</time_frame>
    <description>Measured using Raymond Roy classification where grading ranges from I to III and higher values represent a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial Hemorrhage</measure>
    <time_frame>At discharge or 3 days post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">517</enrollment>
  <condition>Intracranial Aneurysms</condition>
  <condition>Peripheral Aneurysms</condition>
  <arm_group>
    <arm_group_label>Embolization with the PC 400 coils</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PC 400 coils (Penumbra )</intervention_name>
    <description>The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in Â± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.</description>
    <arm_group_label>Embolization with the PC 400 coils</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients enrolled in this study must be those treated according to the cleared indication
        for the PC 400 System which is for the endovascular embolization of:

          -  Intracranial aneurysms

          -  Other neurovascular abnormalities such as arteriovenous malformations and
             arteriovenous fistulae

          -  Arterial and venous embolizations in the peripheral vasculature

        Exclusion Criteria:

          -  Patients in whom endovascular embolization therapies other than Penumbra Coils are
             used will be excluded from this study. However, adjunctive use of balloon and stent
             are acceptable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siu P Sit, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Penumbra Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoag Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658-6100</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3833</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>NY 10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York Upstate Medical Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Sanders Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 28, 2011</study_first_submitted>
  <study_first_submitted_qc>November 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2011</study_first_posted>
  <results_first_submitted>June 1, 2020</results_first_submitted>
  <results_first_submitted_qc>June 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2020</results_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intracranial aneurysms</keyword>
  <keyword>Peripheral aneurysms</keyword>
  <keyword>acute treatment</keyword>
  <keyword>PC 400 System</keyword>
  <keyword>packing density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 10, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT01465841/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Embolization With the PC 400 Coils</title>
          <description>PC 400 coils (Penumbra ): The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in Â± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="517"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="449"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Embolization With the PC 400 Coils</title>
          <description>PC 400 coils (Penumbra ): The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in Â± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="517"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="517"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="517"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="517"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="365"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Packing Density With the Number of Coils Implanted</title>
        <description>The data will be captured at the end of the coiling procedure which is standard for aneurysm studies.</description>
        <time_frame>At immediate post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Embolization With the PC 400 Coils</title>
            <description>PC 400 coils (Penumbra ): The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in Â± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.</description>
          </group>
        </group_list>
        <measure>
          <title>Packing Density With the Number of Coils Implanted</title>
          <description>The data will be captured at the end of the coiling procedure which is standard for aneurysm studies.</description>
          <units>percentage of aneurysm volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Fluoroscopic Exposure</title>
        <description>The total time of fluoroscopic exposure will be captured from the initial recording of the road map to the final angiogram after completion of the coiling procedure.</description>
        <time_frame>At immediate post-procedure</time_frame>
        <population>The analysis population includes all intent-to-treat population. Procedural fluoroscopy time was available for 533 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Embolization With the PC 400 Coils</title>
            <description>PC 400 coils (Penumbra ): The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in Â± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Fluoroscopic Exposure</title>
          <description>The total time of fluoroscopic exposure will be captured from the initial recording of the road map to the final angiogram after completion of the coiling procedure.</description>
          <population>The analysis population includes all intent-to-treat population. Procedural fluoroscopy time was available for 533 subjects.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Procedural Device-related Serious Adverse Events</title>
        <description>Procedural on-the-table serious adverse events will be captured and recorded at the end of the procedure. The duration of the procedure can be variable, depending on the time to access the target lesion and the time to complete the coiling procedure.</description>
        <time_frame>At immediate post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Embolization With the PC 400 Coils</title>
            <description>PC 400 coils (Penumbra ): The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in Â± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Device-related Serious Adverse Events</title>
          <description>Procedural on-the-table serious adverse events will be captured and recorded at the end of the procedure. The duration of the procedure can be variable, depending on the time to access the target lesion and the time to complete the coiling procedure.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Occlusion of the Aneurysm Sac</title>
        <description>Measured using Raymond Roy classification where grading ranges from I to III and higher values represent a worse outcome.</description>
        <time_frame>At immediate post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Embolization With the PC 400 Coils</title>
            <description>PC 400 coils (Penumbra ): The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in Â± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Occlusion of the Aneurysm Sac</title>
          <description>Measured using Raymond Roy classification where grading ranges from I to III and higher values represent a worse outcome.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="465"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Raymond-Roy Occlusion Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Raymond-Roy Occlusion Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Raymond-Roy Occlusion Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intracranial Hemorrhage</title>
        <time_frame>At discharge or 3 days post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Embolization With the PC 400 Coils</title>
            <description>PC 400 coils (Penumbra ): The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in Â± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.</description>
          </group>
        </group_list>
        <measure>
          <title>Intracranial Hemorrhage</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 1 year in accordance to the standard of care at participating hospitals</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Embolization With the PC 400 Coils</title>
          <description>PC 400 coils (Penumbra ): The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in Â± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="517"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital, familial, and genetic disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Disorders</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders and Administration Site Conditions</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary Disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestations</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, Poisoning and Procedural Complications</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and Nutrition Disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and Connective Tissue Disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms Benign, Malignant and Unspecified (incl cysts and polyps)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System Disorders</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric Disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and Urinary Disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, Thoracic and Mediastinal Disorders</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and Medical Procedures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Disorders</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="284" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital, familial, and genetic disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and Labyrinth Disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Disorders</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Disorders</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders and Administration Site Conditions</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary Disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune System Disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestations</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, Poisoning, and Procedural Complications</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and Nutrition Disorders</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muskuloskeletal and Connective Tissue Disorders</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms Benign, Malignant, and Unspecified (inc cysts and polyps)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System Disorders</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric Disorders</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and Urinary Disorders</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, Thoracic and Mediastinal Disorders</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and Subcutaneous Tissue Disorders</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and Medical Procedures</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Disorders</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="517"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michaella Corso</name_or_title>
      <organization>Penumbra, Inc.</organization>
      <phone>415-815-8904</phone>
      <email>mcorso@penumbrainc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

